State Bills related to Drug Prices (2015 - 2018)
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAE
1
StateBillYearTitleStatus (all)Status (simplified)Date of Last ActionAuthorNumber of authorsParty affiliation (all)
Party affiliation (simplified)
TopicsAssociated BillsGeneral summaryKey policyKey policy summaryInclusion criteriaScope of transparencySanctions
2
KentuckyKY HR 1012018Prescription Drug Prices
Failed - Adjourned - HouseElections, ConstitutionalAmendmentsAnd IntergovernmentalAffairs Committee
Failed1/23/2018
Cantrell (D) Additional Authors: Burch (D);Wayne (D);Jenkins (D);Marzian (D);Graham (D);Owens (D);Donohue (D);Scott (D)
9DemocraticDemocratic
Pricing and Payment - Industry, Medicaid Use and Cost - Rx Drugs
None
Non-binding resolution, encourages the United States Congress to pass legislation that permits the United States Centers for Medicare and Medicaid Services (CMS) to negotiate with pharmaceutical companies for fair and reasonable prices on prescription drugs.
Medicare negotiation
Non-binding resolution encouraging Medicare and Medicaid negotiation
--
3
New JerseyNJ ACR 1252018Congressional and Presidential Resolution
Pending - Assembly HealthAnd Senior Services Committee
Pending2/1/2018McKeon (D)1DemocraticDemocratic
Pricing and Payment - Industry, Other Prescription Drug Measures
None
Urges Congress and President to require federal government to negotiate Medicare prescription drug prices.
Medicare negotiation
Non-binding resolution encouraging Medicare negotiation
--
4
New JerseyNJ ACR 2072017Congressional Resolution
Pending - AssemblyFinancial InstitutionsAnd Insurance Committee
Pending9/19/2016
McKeon (D) Additional Authors: Coughlin (D)
2DemocraticDemocraticPricing and Payment - IndustryNone
Urges Congress and President to require the federal government to negotiate Medicare prescription drug prices.
Medicare negotiation
Non-binding resolution encouraging Medicare negotiation
--
5
New JerseyNJ ACR 2022015Medicare Prescription Drug Prices
Pending - Carryover - Assembly HealthAnd Senior Services Committee
Pending10/23/2014O'Donnell (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Urges Congress and the President to require the federal government to negotiate Medicare prescription drug prices.
Medicare negotiation
Non-binding resolution encouraging Medicare negotiation
--
6
ColoradoCO S 802018
Wholesale Canadian Drug Importation Program
Failed - Adjourned -Postponed Indefinitely
Failed1/12/2018
Aguilar (D) Additional Authors: Lontine (D)
2DemocraticDemocraticPricing and Payment - IndustryNone
Concerns wholesale importation of pharmaceuticals from Canada for resale to Colorado residents.
Parallel import
Order the State Departament to design a wholesale importation program that addresses the requirements of 21 U.S.C. sec. 384
--
7
LouisianaLA H 3842018Drugs and Prescription
Failed - Adjourned - House HealthAnd Welfare Committee
Failed3/12/2018Talbot (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Creates and provides for a state prescription drug importation program.
Parallel import
Create the Canadian Prescription Drug Importation Program pursuant to 21 U.S.C. 384
--
8
LouisianaLA HCR 662018Drugs and Prescription
Failed - Adjourned - Senate HealthAnd Welfare Committee
Failed4/24/2018Talbot (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Non-binding joint resolution, requests a study concerning the prospective establishment of a state prescription drug importation program.
Parallel import
Non-binding resolution urging a study on the prospective establishment of a State program for importation of prescription drugs from Canada
--
9
MaineME LR 19302016Cosmetic ActFailed - Adjourned - LegislatureFailed5/15/2015Martin Jo (D)1DemocraticDemocraticPricing and Payment - Industry, AccessNone
Allows Maine residents to personally import medications as permitted under the federal food, drug, and cosmetic act.
Parallel import---
10
MaineME LR 7002016Purchase of Prescription Drugs From CanadaFailed - Adjourned - LegislatureFailed1/15/2015Senator Brakey1DemocraticDemocratic
Pricing and Payment - Industry, Access, Safety and Errors - Rx Drugs
None
Authorizes the purchase of prescription drugs from canada.
Parallel import---
11
MaineME H 9682016Cosmetic ActFailed - DiedFailed5/15/2015Martin Jo (D)1DemocraticDemocraticAccess, Safety and Errors - Rx DrugsNone
Under the Federal Food, Drug, and Cosmetic Act, the importation of unapproved new prescription drugs, including foreign-made versions of prescription drugs that have been approved by the federal FDA, is prohibited. However, the FDA has developed guidance that allows the personal importation of certain drugs. This bill, using the guidance developed by the Food and Drug Administration, enacts the Maine Pharmaceutical Drug Safety Act to allow an individual in Maine to import prescription drugs from Canada or certain member countries of the European Union for use by that individual or a member of that individual's immediate family. The country from which the prescription drug is to be imported must meet specific criteria regarding regulation of its pharmacies and pharmacists, as determined by the United States Secretary of State. The prescription drug to be imported must also meet specific requirements, importation of controlled substances and prescription drugs for sale or resale is specifically prohibited.
Parallel import--
12
MaineME H 9682015Cosmetic ActFailed - DiedFailed5/15/2015Martin Jo (D)1DemocraticDemocraticAccess, Safety and Errors - Rx DrugsNone
Under the Federal Food, Drug, and Cosmetic Act, the importation of unapproved new prescription drugs, including foreign-made versions of prescription drugs that have been approved by the federal FDA, is prohibited. However, the FDA has developed guidance that allows the personal importation of certain drugs. This bill, using the guidance developed by the Food and Drug Administration, enacts the Maine Pharmaceutical Drug Safety Act to allow an individual in Maine to import prescription drugs from Canada or certain member countries of the European Union for use by that individual or a member of that individual's immediate family. The country from which the prescription drug is to be imported must meet specific criteria regarding regulation of its pharmacies and pharmacists, as determined by the United States Secretary of State. The prescription drug to be imported must also meet specific requirements, importation of controlled substances and prescription drugs for sale or resale is specifically prohibited.
Parallel import--
13
MaineME LR 7002015Purchase of Prescription Drugs From CanadaPending - LegislaturePending1/15/2015Senator Brakey1RepublicanRepublican
Pricing and Payment - Industry, Access, Safety and Errors - Rx Drugs
None
Authorizes the purchase of prescription drugs from canada.
Parallel import--
14
MassachusettsMA H 10272016Purchase of Prescription Drugs from CanadaPending - House Study OrderPending3/11/2015Sannicandro (D)1DemocraticDemocraticPricing and Payment - Industry, AccessNone
Establishes a state-law based process related to the purchase of prescription drugs from Canada.
Parallel import--
15
MassachusettsMA H 10272015Purchase of Prescription Drugs from Canada
Pending - Joint Committee on Health CareFinancing
Pending3/11/2015Sannicandro (D)1DemocraticDemocraticAccessNone
Establishes a state-law based process related to the purchase of prescription drugs from Canada.
Parallel import--
16
MissouriMO S 7222018Prescription Drug Importation Study
Failed - Adjourned - HouseEconomic Development Committee
Failed1/3/2018Sater (R)1RepublicanRepublican
Pricing and Payment - Industry, Clinical Trials and Right to Try, Other Prescription Drug Measures
None
Provides that the state department of health and senior services ''shall conduct a study regarding the processes by which the state may import certain prescription drugs from other countries for eventual consumption by Missouri consumers.''
Parallel import--
17
MontanaMT D 13882015
Montanans to Purchase Prescription Drugs In Canada
Failed - DraftFailed12/5/2014Hayman (D)1DemocraticDemocratic
Pricing and Payment - Industry, Access, Safety and Errors - Rx Drugs
None
Permits Montanans to purchase prescription drugs in Canada, relates to health care services.
Parallel import--
18
New YorkNY A 22882016
Protection From Prescription Drug Re-importation
Pending - Assembly ConsumerAffairsAndProtection Committee
Pending1/15/2015
Englebright (D) Additional Authors: Ryan (D)
2DemocraticDemocraticPricing and Payment - Industry, AccessNone
Relates to consumer protection from prescription drug re-importation and unlawful practices and enforcement and penalties.
Parallel import--
19
New YorkNY A 22882015
Protection From Prescription Drug Re-importation
Pending - Assembly ConsumerAffairsAndProtection Committee
Pending1/15/2015
Englebright (D) Additional Authors: Ryan (D)
2DemocraticDemocraticPricing and Payment - Industry, AccessNone
Relates to consumer protection from prescription drug re-importation and unlawful practices and enforcement and penalties.
Parallel import--
20
OklahomaOK S 13812018Prescription Drugs
Failed - Adjourned - Senate HealthAnd Human Services Committee
Failed2/5/2018Standridge (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Requires the Oklahoma Health Care Authority to submit to HHS no later than August 2018, an application for the approval of a program to allow for the importation of prescription drugs from Canada into the state under the provisions of federal law, including certification by the HHS Secretary that ""�'importation of Canadian prescription drugs will pose no additional risk to the public's health and safety and result in a significant reduction in the cost of covered products."" The OK Health Care Authority shall study how to gain federal approval for the state to import drugs by implementing a pilot to reduce prescription drug costs for Oklahoma consumers and state agencies. The study will include: a plan for operating the prescription pilot drug program, a plan to ensure that drugs under the prescription drug importation program meet federal and state standards for safety and effectiveness, examples of five to seven highly prescribed drugs with a large cost differential between Canadian and U.S. average prices whose importation will create significant consumer savings (with exclusions for biologics, infused or injectable products or controlled substances), and an estimate of the total potential consumer and state agency savings through importation. [Updated 3/5/2018]
Parallel import--
21
TexasTX H 38362017
Importing Pharmaceuticals from a Foreign Country
Failed - Adjourned - HousePublic Health Committee
Failed3/9/2017Burrows (R)1RepublicanRepublicanOther Prescription Drug MeasuresNone
Relates to importing pharmaceuticals from a foreign country.
Parallel import--
22
UtahUT H 1632018Prescription Drug Importation ProgramFailed - Enacting Clause StruckFailed2/14/2018
Thurston (R) Additional Authors: Henderson (R)
2RepublicanRepublican
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs
None
Requires the Department of Health to design a wholesale Canadian prescription drug importation program, apply for approval of the program by the Secretary of the U.S. Department of Health and Human Services, and, if the drug importation program is approved, to implement the provisions of the program. The state-run prescription drug importation program would import select, higher-cost drugs that are already licensed for sale in Canada, where sponsors estimate ''prescription drugs cost 30 percent less than in the United States.'' whole-sale importation program
Parallel import--
23
UtahUT H 4202017Prescription Drug Importation StudyFailed - Enacting Clause StruckFailed2/21/2017Thurston (R)1RepublicanRepublican
Pricing and Payment - Industry, Other Prescription Drug Measures
None
Requires the Department of Health to study and report on prescription drug importation fir use by state residents.
Parallel import--
24
VermontVT S 1752018Wholesale Importation of Prescription DrugsEnacted - Act No. 133Enacted05/16/2018 - Enacted
Ashe (D) Additional Authors: Lyons (D);Ayer (D);Pearson (P);Sirotkin (D)
5DemocraticDemocratic
Pricing and Payment - Industry, Other Prescription Drug Measures, Cost Sharing and Deductibles - Consumers
None
Relates to the wholesale importation of prescription drugs into Vermont. Creates a wholesale importation program to purchase high-cost drugs through authorized wholesalers, who will purchase the drugs in Canada and make them available to Vermonters through an existing supply chain that includes local pharmacies. The bill requires Vermont's Agency for Human Services, in consultation with stakeholders and the federal government, to design and submit an importation proposal to the state legislature on or before Jan. 1, 2019 and further requires the agency to submit its proposal to the federal government on or before July 1, 2019, for final approval. The importation program must be operational within six months of approval of the financing strategy, certification, and federal government sign-off. Also addresses the impact of prescription drug costs on health insurance premiums. [Updated 5/7/2018]
Parallel import--
25
West VirginiaWV H 42942018
State Administered Wholesale Drug Importation Program
Failed - Adjourned - House HealthAnd Human Resources Committee
Failed1/25/2018Bates (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Creates a state-administered wholesale drug importation program. Gives the state authority to designate a state agency to function as a drug wholesaler to import pharmaceuticals from Canada to providedrugs to West Virginians, while only importing ''those prescription pharmaceuticals expected to generate substantial savings for West Virginia's consumers.''
Parallel import--
26
New JerseyNJ S 9772018
Publicly Funded and Researched Drugs Charges
Pending - Senate Health, Human ServicesAnd Senior Citizens Committee
Pending1/16/2018Singleton (D)1DemocraticDemocratic
Pricing and Payment - Industry, Other Prescription Drug Measures
None
Prohibits excessive charges for drugs developed by publicly funded research. ''If a drug, biologic, or other health care technology approved by the federal Food and Drug Administration was developed, partially or entirely, through research and development that is directly or indirectly supported by the federal or State government, it shall be unlawful for any person to sell, offer to sell, or advertise for sale the drug, biologic, or technology to any purchaser in this State at a unit price that is greater than the benchmark unit price'' established in this section, or that constitutes discriminatory pricing. The benchmark unit price is the lowest price charged to countries in the Organization for Economic Co-Operation and Development for the same drug, biologic, or technology, that have the largest gross domestic product with a per capita income that is not less than half that in the United States. [updated 2/5/2018]
Price safeguards for publicly-funded drugs
Prohibits discriminatory pricing for drugs partially or entirely supported with federal funds, using OECD as benchmark
Federally funded drugs-
27
CaliforniaCA A 4632016
Pharmaceutical Cost Transparency Act of 2016
Failed - ASSEMBLYFailed1/4/2016Chiu (D)1DemocraticDemocratic
Pricing and Payment - Industry, Other Prescription Drug Measures
None
Requires each manufacturer of a prescription drug that has a wholesale acquisition cost of $10,000 or more annually or per course of treatment, to file a disclosure report on the costs for each qualifying drug to the Office of Statewide Health Planning and Development. Requires the Office to issue a report to the Legislature outlining the information in the manufacturer's report and to post the report on its Internet Web site. Requires the Office to convene an advisory workgroup to develop a reporting form. Relates to reports confidentiality. [Filed 2015, final action in 2016]
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
28
CaliforniaCA A 4632015
Pharmaceutical Cost Transparency Act of 2015
Pending - Carryover - Assembly Health Committee
Pending2/23/2015Chiu (D)1DemocraticDemocratic
Pricing and Payment - Industry, Other Prescription Drug Measures
None
Requires each manufacturer of a prescription drug that has a specified wholesale acquisition cost to file a report on the costs for each qualifying drug to the Office of Statewide Health Planning and Development. Requires the Office to issue a report to the Legislature outlining the information in the manufacturer's report and to post the report on its Internet Web site. Requires the Office to convene an advisory workgroup to develop a form for such reporting requirements.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
29
ColoradoCO H 10092018Diabetes Drug Pricing Transparency Act
Failed - Adjourned -Postponed Indefinitely
Failed4/19/2018
Roberts (D) Additional Authors: Donovan (D)
2DemocraticDemocraticPricing and Payment - IndustryNone
Establishes the Diabetes Drug Pricing Transparency Act, requires the State Board of Health to compile a list of prescription insulin drugs along with the wholesale acquisition cost of each drug and post such list on its website, requires the State Board to prepare a report form to be completed by drug manufacturers of prescription drugs as appears on the compiled list, requires pricing reports to be submitted by insurers issuing health coverage plans, makes appropriations.
R&D transparency
Manufactures of selected diabetes drugs shall disclose the aggregate amount of R&D cost atributable to diabetes drugs
Drugs for diabetesR&D costs
30
ColoradoCO H 11022016
Drug Production Costs Transparency Requirements
Failed - Adjourned -Postponed Indefinitely
Failed1/19/2016
Ginal (D) Additional Authors: Kefalas (D);Salazar (D);Buckner (D);Aguilar (D);Lee (D);Newell (D);Vigil (D);Hullinghorst (D);Roberts (R);Lontine (D)
11BipartisanBipartisanPricing and Payment - IndustryNone
Concerns a requirement that drug manufacturers report production costs for certain high-cost prescription drugs.
R&D transparency
Manufacturers of drugs with wholesale prices of 50,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
31
ConnecticutCT H 53842018Prescription Drug CostsEnacted - Act No. 18-41Enacted05/31/2018 - Enacted
Joint Insurance and Real Estate Additional Authors: Mushinsky (D);Looney (D);Gentile (D);Rojas (D);Scanlon (D);Kennedy (D);Winkler (D);Young (D)
8DemocraticDemocratic
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs, Pharmacy Benefit Managers (PBM)
None
Requires manufacturers to disclose net drug cost after rebates and to inform the state Office of Health Strategy when a company has submitted a drug approval application to the US Food and Drug Administration, requires disclosing price increase justifications to the Office, which must be posted on the state website. Requires the Office of Health Strategy to annually list the top 10 drugs whose wholesale acquisition cost has increased by 25 percent and that represent substantial state spending. Imposes additional disclosure and reporting requirements on pharmacy benefits managers, health carriers, pharmaceutical manufacturers, the Office of Health Strategy and the Insurance Department concerning prescription drug rebates and the cost of prescription drugs.
R&D transparency
Manufacturers of a list of up to 10 drugs selected by price and public health importance shall report aggregate, company-level R&D costs
Drugs with high prices and therapeutic criteria
Aggregate, company-level R&D costs
32
ConnecticutCT S 7372017Prescription Drug Cost TransparencyFailed - DiedFailed1/26/2017Kennedy (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Concerns prescription drug cost transparency, explores options to help reduce the high costs of prescription drugs and educate the public and state agencies that pay for prescription drugs as to the costs of such drugs.
R&D transparency
Manufacturers of every drug made available in Connecticut shall report R&D costs, clinical trials costs
All drugs made available in the StateR&D costs, clinical trial costs
33
IndianaIN H 11502017Prescription Drug Cost Reporting
Failed - Adjourned - House Public Health Committee
Failed1/9/2017Taylor (D)1DemocraticDemocratic
Pricing and Payment - Industry, Medicaid Use and Cost - Rx Drugs
None
Relates to prescription drug cost reporting, requires the office of the secretary of family and social services to identify any prescription drug under the Medicaid program for which the annual wholesale cost or the per course cost of treatment of the drug is at least $10,000, and directs the office to notify the manufacturer that the manufacturer is required to prepare a report on the drug to the drug utilization review board, Specifies requirements of the report.
R&D transparency
Manufacturers of drugs under Medicaid with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs in Medicaid with high prices
R&D costs, clinical trial costs, subsidies
34
MarylandMD H 6662017Expensive Drugs Manufacturer
Failed - Adjourned - House HealthAnd Government Operations Committee
Failed2/1/2017
Bromwell (D) Additional Authors: Lewis R (D);Jackson (D);Hill (D);Hettleman (D);Fennell (D);Ebersole (D);Chang (D);Brooks (D);Barnes D (D);Atterbeary (D);Fraser-Hidalgo (D);Washington A (D);Wilson (D);Washington M (D);Miller A (D);Luedtke (D);Kelly A (D);Knotts (D);Korman (D);Proctor S (D);Sanchez (D);Young P (D);Young (D);Tarlau (D);Sydnor (D);Sample-Hughes (D);Platt (D);Patterson (D);Morales (D);Moon (D);McCray (D);Lisanti (D);Lierman (D);Lam (D);Krimm (D);Cullison (D);Clippinger (D);Dumais (D);Gaines (D);Jones A (D);Turner F (D);Vallario (D);Sophocleus (D);Rosenberg (D);Oaks (D);McIntosh (D);Frush (D);Howard (D);Hixson (D);Healey (D);Branch (D);Davis D (D);Barkley (D);Gutierrez (D);Haynes (D);Carr (D);Frick (D);Walker (D);Waldstreicher (D);Valderrama (D);Stein (D);Pena-Melnyk (D);Lafferty (D);Glenn (D);Conaway (D);Beidle (D);Barnes (D);Anderson (D);Kaiser (D);Jameson (D);Holmes (D);Barve (D)
73DemocraticDemocraticPricing and Payment - IndustryNone
Requires, on or before March 31 each year, the manufacturer of an expensive drug sold or offered for sale in the state to file with the Secretary of Health and Mental Hygiene a specified annual report, establishes the Drug Price Transparency Advisory Committee, requires a manufacturer of an expensive drug to file a notice with the Secretary before increasing a specified price or a specified cost by more than a specified percentage or amount during specified periods of time.
R&D transparency
Manufacturers of drugs with wholesale prices of 2,500 or more per year or treatment shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
35
MassachusettsMA S 22112018
Health Empowerment and Health Care Affordability
Pending - HOUSEPending11/9/2017Senate FloorJoint commiteeJoint commiteeBipartisan
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs, Pharmacy Benefit Managers (PBM)
MA S 2202 - New Draft of
Transparency to prevent price gouging. Provides that the state Health Policy Commission (HPC) require testimony at annual cost trend hearings from PBMs & pharmaceutical manufacturers, to include ""factors underlying prescription drug costs and prices increases, the impact of manufacturer rebates, discounts and other price concessions on net pricing, the availability of alternative drugs or treatments and any other matters as determined by the commission. Also requires manufacturers to provide early notice relative to drugs and biologics in the development pipeline to HPC, hospitals, surgical centers and surcharge payors. Also HPC must ""conduct annual study of pipeline, generic and biosimilars that have significant impact on health expenditures."" PBMs/Manufacturers must report to the state: Wholesale acquisition cost (WAC) changes, company-level and product-specific R&D, price paid to acquire the drug (if applicable), 5-year WAC increase history, annual marketing and advertising expenditures, factors contributing to WAC changes. [Updated 12/27/2017]
R&D transparency
Manufacturers and PBMs shall report aggregate, company-level and product-specific R&D costs, as required by an State commission. Information is keep secret.
All drugs as required by a State commission
Aggregate, company-level R&D costs
36
MassachusettsMA H 12282018Pharmaceutical Drug Prices
Pending - Joint Committee onPublic Health
Pending1/23/2017
Tosado (D) Additional Authors: Balser (D);Walsh (D);Whelan (R);Ultrino (D);Muratore (R);Gentile (D);Heroux (D);DiZoglio (D);Decker (D);Cutler (D);Cantwell (D);Provost (D);Scibak (D);Kocot (D);Connolly (D)
16BipartisanBipartisanPricing and Payment - IndustryNone
Relates to cost control of pharmaceutical drug prices. Authorizes the state to appoint a commission to develop a list of the top 20 selling drugs in the state and other drugs based on an enumerated list of price and use factors. For each specified drug, manufacturers must provide a detailed set of reports including manufacturing and marketing costs, costs to public and private purchasers, and other specified factors. The Commission will promulgate regulations, violations may subject a manufacturer to penalties up to $100,000 for each failure to comply. [updated 8/15/17]
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug" list based on price, access and therapeutic criterias shall report R&D costs, subsidies
Drugs with high prices and therapeutic criteria
R&D costs, subsidies
37
MassachusettsMA S 22022018
Health Empowerment and Health Care Affordability
Pending - Replaced by New DraftPending11/9/2017Ways and Means CmtJoint commiteeJoint commiteeBipartisan
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs, Pharmacy Benefit Managers (PBM)
MA S 2190 - New Draft of;MA S 2211 - New Draft see
Transparency to prevent price gouging. Provides that the state Health Policy Commission (HPC) require testimony at annual cost trend hearings from PBMs & pharmaceutical manufacturers, to include ""factors underlying prescription drug costs and prices increases, the impact of manufacturer rebates, discounts and other price concessions on net pricing, the availability of alternative drugs or treatments and any other matters as determined by the commission. Also requires manufacturers to provide early notice relative to drugs and biologics in the development pipeline to HPC, hospitals, surgical centers and surcharge payors. Also HPC must ""conduct annual study of pipeline, generic and biosimilars that have significant impact on health expenditures."" PBMs/Manufacturers must report to the state: Wholesale acquisition cost (WAC) changes, company-level and product-specific R&D, price paid to acquire the drug (if applicable), 5-year WAC increase history, annual marketing and advertising expenditures, factors contributing to WAC changes. [Updated 12/27/2017]
R&D transparency
Manufacturers shall report "aggregate, company-level and product-specific" R&D costs, as required by a State commission
All drugs as required by a State commission
R&D costs
38
MassachusettsMA S 6272018Prescription Drug Price TransparencyPending - Senate Second ReadingPending2/22/2017Forry (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Relates to cost control of pharmaceutical drug prices. Authorizes the state to appoint a commission to develop a list of the top 20 selling drugs in the state and other drugs based on an enumerated list of price and use factors. For each specified drug, manufacturers must provide a detailed set of reports including manufacturing and marketing costs, costs to public and private purchasers, and other specified factors. The Commission will promulgate regulations, violations may subject a manufacturer to penalties up to $100,000 for each failure to comply. [updated 8/15/17]
R&D transparency
Manufacturers of drugs with price increases shall report total R&D cost, clinical trials costs, subsidies
Drugs with price increases
R&D costs, clinical trial costs, subsidies
39
MassachusettsMA S 6522018Pharmaceutical Price Gouging PreventionPending - Senate Second ReadingPending2/22/2017Montigny (D)1DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Promotes transparency and prevent price gouging of pharmaceutical drug prices.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment, with price increases, and 10 costliest drugs shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increasesR&D costs, clinical trial costs
40
MassachusettsMA S 6522017Pharmaceutical Price Gouging Prevention
Pending - Joint Committee on Health CareFinancing
Pending2/22/2017Montigny (D)1DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Promotes transparency and prevent price gouging of pharmaceutical drug prices.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment, with price increases, and 10 costliest drugs shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increasesR&D costs, clinical trial costs
41
MassachusettsMA S 10482016
Transparency and Cost Control of Pharmaceutical Drug
Pending - Senate Study OrderPending4/15/2015Montigny (D)1DemocraticDemocraticPricing and Payment - Industry, AccessNone
Promotes transparency and cost control of pharmaceutical drug prices. Requires that a state commission ""shall develop a list of critical prescription drugs for which there is a substantial public interest in understanding the development of its pricing. In developing the list, the commission shall consider the following factors: (i) the cost of the drug to public health care programs, including the office of Medicaid and the group insurance commission, (ii) the current cost of the drug in the commonwealth, (iii) the extent of utilization of the drug within the Commonwealth, and (iv) potential impact of the cost of the drug on the commonwealth's achievement of the statewide health care cost growth benchmark.'' If the commission ''determines that a prescription drug is significantly high, then the commission may set the maximum allowable price that the manufacturer can charge for that prescription drug that is sold for use'' in the state.
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
42
MinnesotaMN S 28012018Health Care
Failed - Adjourned - Senate HealthAnd Human ServicesFinanceAndPolicy Committee
Failed3/1/2018Jensen S (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Establishes the state Prescription Drug Cost Review and Rate Setting Act, creates a prescription drug cost review commission and rate-setting requirements, requires a report, appropriates money. Focuses on ""Excess costs"" defined as ''the cost of a prescription drug product that either: exceeds the therapeutic benefit relative to other therapeutic options or alternative treatments, or is not sustainable to public and private health care systems over a ten-year time period.'' Patented product manufacturers must notify the commission if they plan to increase the cost (WAC) of a patent-protected brand name drug by more than $10,000 during any 12-month period, or intend to introduce to market a brand name drug that has a cost of $30,000 per year or per course of treatment. Notice must be at least 30 days prior to effective date of the increase or introduction and must include a justification. Generic manufacturers must notify any increase of 25% or more than $300 during any 12-month period.
R&D transparency
A drug cost review commision that reviews whether prices are excesive can take R&D, as shown in tax fillings, into consideration
Drugs with high pricesR&D costs
43
MinnesotaMN H 25252016Health
Failed - Adjourned - House HealthAnd Human Services Reform Committee
Failed3/8/2016Mullery (DFL)1
Democratic–Farmer–Labor
OthersPricing and Payment - Industry
MN S 2947 - Companion
Requires cost disclosure and transparency by drug manufacturers for qualifying prescription drugs. ''to make information available to the public about the cost of ultra-high-priced pharmaceuticals ($10,000 or more annually) in order to make pharmaceutical pricing as transparent as the pricing in other sectors of the health care industry."" Requires annual cost reporting on the most expensive drugs that would allow policy makers, government agencies, and others to understand costs for these important products.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
44
MinnesotaMN S 29422016Health
Failed - Adjourned - SenateFinance Committee
Failed3/30/2016Franzen (DFL)1
Democratic–Farmer–Labor
OthersPricing and Payment - Industry
MN H 2526 - Companion
Requires cost disclosure and transparency for qualifying prescription drugs, with a wholesale acquisition cost (WAC) of $1,000 or more annually. Declares that ''the legislature finds that there should be annual cost reporting on the most expensive drugs that would allow policymakers, government agencies, and others to understand costs for these important products.''
R&D transparency
Manufacturers of drugs with wholesale prices of 1,000 or more per month or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
45
NevadaNV A 2152017
Reporting of Information Relating to Prescription Drugs
Failed - DiedFailed2/13/2017Joiner (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Requires Rx manufacturers to reporting of certain information on drugs with a wholesale price of at least $10,000 or an annual price increase of 25%, relating to the manufacturer's cost associated with their prescription drugs.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
46
New JerseyNJ A 5832018
Prescription Drug Review Commission Establishment
Pending - Assembly HealthAnd Senior Services Committee
Pending1/9/2018
Moriarty (D) Additional Authors: Danielsen (D)
2DemocraticDemocraticPricing and Payment - IndustryNone
Establishes the NJ Prescription Drug Review Commission, requires prescription drug production costs be reported. Specifically, ''The commission shall develop a list of critical prescription drugs made available in New Jersey for which there is a substantial public interest in understanding the development of pricing for the drugs.'' Reports will the cost of the drug to public health care programs including, the Medicaid and NJ FamilyCare programs, as well as retail or insurance related prices. Also includes extent of product use and the availability and cost of comparable or therapeutically equivalent courses of treatment. It will ''require the manufacturer of the drug to report: total cost of production, and approximate cost of production per dose, marketing and advertising costs for the drug, research and development costs of the drug, including: (a) R & D paid with public funds, (b) after-tax research and development costs paid by the manufacturer, and (c) research and development costs paid by third parties, and other financial factors. ''If the commission determines that the cost of a prescription drug is excessively high, the commission may set the maximum allowable price that the manufacturer can charge for that prescription drug when sold for use in New Jersey.'' [Added 1/22/2018]
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug list" based on price, access and therapeutic criterias shall report R&D costs, subsidies
Drugs with high prices and therapeutic criteria
R&D costs, subsidies
47
New JerseyNJ S 9832018Prescription Drug Review Commission
Pending - Senate Health, Human ServicesAnd Senior Citizens Committee
Pending1/16/2018Vitale (D)1DemocraticDemocratic
Pricing and Payment - Industry, Other Prescription Drug Measures
None
Establishes a state Prescription Drug Review Commission, requires production costs be reported for certain prescription drugs. ''The commission shall develop a list of critical prescription drugs made available in New Jersey for which there is a substantial public interest in understanding the development of pricing for the drugs. In developing the list, the commission shall consider the following factors: (1) the cost of the drug to public health care programs including, but not limited to, the Medicaid and NJ FamilyCare programs, (2) the current cost of the drug in the State, (3) the extent of utilization of the drug within the State, (4) the availability and cost of comparable or therapeutically equivalent courses of treatment, (5) the rate at which the drug is deemed to produce successful outcomes when used to treat the conditions for which it is most commonly prescribed, and (6) such other objectively quantifiable factors as the commission determines to be relevant to evaluating the significance of the availability of the drug in New Jersey.'' For each prescription drug that the commission places on the critical prescription drug list pursuant to subsection a. of this section, the commission shall require the manufacturer of the drug to report the following information to the commission: (1) total cost of production, and approximate cost of production per dose, (2) research and development costs of the drug, including: (a) research and development costs that are paid with public funds, (b) after-tax research and development costs paid by the manufacturer, and (c) research and development costs paid by third parties, (3) marketing and advertising costs for the drug, apportioned by marketing activities that are directed to consumers, marketing activities that are directed to prescribers, and the total cost of all marketing and advertising that is directed primarily to New Jersey consumers and prescribers, (4) the prices for the drug that are charged to purchasers outside the United States, by country, for a representative set of countries determined by the commission, (5) prices charged to typical New Jersey purchasers, including, but not limited to, pharmacies, pharmacy chains, pharmacy wholesalers, or other direct purchasers, and (6) true net typical prices charged to prescription drug benefit managers for distribution in New Jersey. [Updated 2/5/2018]
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug list" based on price, access and therapeutic criterias shall report R&D costs, subsidies
Drugs with high prices and therapeutic criteria
R&D costs, subsidies
48
New JerseyNJ A 7622017Prescription Drug Review Commission
Pending - Assembly HealthAnd Senior Services Committee
Pending1/27/2016Moriarty (D)1DemocraticDemocraticPricing and Payment - Industry
NJ S 3088 - Identical
Establishes Prescription Drug Review Commission, requires transparency by manufacturers, including production costs to be reported for certain high-cost prescription drugs.
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug list" based on price, access and therapeutic criterias shall report R&D costs, subsidies
Drugs with high prices and therapeutic criteria
R&D costs, subsidies
49
New JerseyNJ A 7622016Prescription Drug Review Commission
Pending - Assembly HealthAnd Senior Services Committee
Pending1/27/2016Moriarty (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Establishes Prescription Drug Review Commission, requires transparency by manufacturers, including production costs to be reported for certain high-cost prescription drugs.
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug" list based on price, access and therapeutic criterias shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
50
New YorkNY A 29392018Prescription Drug Cost Transparency
Pending - Assembly Health Committee
Pending1/23/2017
McDonald J (D) Additional Authors: Ortiz (D);Morinello (R);Walsh (R)
4BipartisanBipartisanPricing and Payment - IndustryNone
Relates to prescription drug cost transparency.
R&D transparency
Manufacturers of drugs with wholesale prices of 1,000 or more per month or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
51
New YorkNY A 29392017Prescription Drug Cost Transparency
Pending - Assembly Health Committee
Pending1/23/2017
McDonald J (D) Additional Authors: Ortiz (D);McDonald J (D);Morinello (R);Walsh (R)
5BipartisanBipartisanPricing and Payment - IndustryNone
Relates to prescription drug cost transparency.
R&D transparency
Manufacturers of drugs with wholesale prices of 1,000 or more per month or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
52
New YorkNY A 100262016Prescription Drug Cost Transparency
Pending - Assembly Health Committee
Pending5/6/2016McDonald J (D)1DemocraticDemocraticPricing and Payment - Industry, AccessNone
Requires prescription drug cost transparency. The manufacturer of a pharmaceutical drug that has a wholesale acquisition cost of one thousand dollars for a thirty day supply or cumulative price increase of three times the consumer price index in a 3-month period, shall file a report
R&D transparency
Manufacturers of drugs with wholesale prices of 1,000 or more per month shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
53
New YorkNY A 82652016
Pharmaceutical Cost Transparency Act of 2015
Pending - Assembly Health Committee
Pending6/16/2015Blake (D)1DemocraticDemocraticPricing and Payment - Industry, AccessNone
Enacts the pharmaceutical cost transparency act of 2015 requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
54
New YorkNY S 53382016
Pharmaceutical Cost Transparency Act of 2015
Pending - Senate Health Committee
Pending1/20/2016
Diaz Ru (D) Additional Authors: Perkins (D)
2DemocraticDemocraticPricing and Payment - Industry, AccessNone
Enacts the Pharmaceutical Cost Transparency Act of 2015 requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of a certain sum or more annually or per course of treatment.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
55
New YorkNY S 76862016Prescription Drug Cost Transparency
Pending - Senate Health Committee
Pending5/12/2016Hannon (R)1RepublicanRepublican
Pricing and Payment - Industry, Access, Cost Sharing and Deductibles - Consumers
None
Relates to prescription drug cost transparency. Requires manufacturers of a brand and generic medication that is made available in New York state to file a report annually on pharmaceutical costs for products with a price of $1,000 or more for a 30 day supply or an increased prices within a 3-month period of 3 times the CPI (consumer price index) with detailed statistics on each of 15 segments of actual costs including research, clinical trials, production, marketing, direct-to-consumer advertising, prescriber education, beginning in 2017 Resulting ''information shall be made publicly available on the department's website.'' [Added 5/16/2016]
R&D transparency
Manufacturers of drugs with wholesale prices of 1,000 or more per month shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
56
New YorkNY A 82652015
Pharmaceutical Cost Transparency Act of 2015
Pending - Assembly Health Committee
Pending6/16/2015Blake (D)1DemocraticDemocraticPricing and Payment - Industry, AccessNone
Enacts the pharmaceutical cost transparency act of 2015 requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
57
New YorkNY S 53382015
Pharmaceutical Cost Transparency Act of 2015
Pending - Senate Health Committee
Pending5/13/2015
Diaz Ru (D) Additional Authors: Perkins (D)
2DemocraticDemocraticPricing and Payment - Industry, AccessNone
Enacts the pharmaceutical cost transparency act of 2015 requiring prescription drug manufacturers to file a report disclosing certain financial information pertaining to prescription drugs which have a wholesale acquisition cost of $10,000 or more annually or per course of treatment.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
58
North CarolinaNC H 8392016Pharmaceutical Drugs Cost Reporting
Failed - Adjourned - House Health Committee
Failed4/15/2015
Collins (R) Additional Authors: Saine (R);Bell J (R);Hanes (D)
4BipartisanBipartisanPricing and Payment - Industry, AccessNone
Cost and price transparency. Requires manufacturers of pharmaceutical drugs to report cost and utilization information. For seven specified categories of drugs (including cancer and all biologics) brand manufacturers would report: (1) Total costs derived in the production of the drug, (2) Average wholesale cost including increases by month over a 5-year period, (3) Total research and development costs paid by the manufacturer, (4) Total administrative costs, marketing and advertising costs for the promotion of the drug, and costs associated with direct to consumer coupons and amount redeemed, (5) Total profit as represented in total dollars and a percentage of total company profit derived from the sale of the drug, and (6) Total amount of financial assistance the manufacturer has provided through patient prescription assistance programs.
R&D transparency
Manufacturers of every drug made available in North Carolina shall report cost R&D costs
All drugs made available in the StateR&D costs
59
OregonOR S 7932017Prescription Drug Manufacturer Reporting
Failed - Adjourned - Senate Health Care Committee
Failed2/14/2017
Steiner Hayward (D) Additional Authors: Steiner Hayward (D);Nosse (D)
3DemocraticDemocraticPricing and Payment - IndustryNone
Requires prescription drug manufacturer to report to Department of Consumer and Business Services prices and increases in prices of manufacturer's prescription drugs sold in the state, requires manufacturer to provide justification for increase in price greater than a specified percent for prescription drugs sold in the state longer than a specified number of months, requires department to order manufacturer to refund excessive price increases to purchasers of prescription drugs.
R&D transparency
Manufacturers of drugs with price increases shall report total R&D cost
Drugs with high pricesR&D costs
60
OregonOR H 34862015Manufacturer of Prescription DrugFailed - DiedFailed3/11/2015Keny-Guyer (D)1DemocraticDemocratic
Biologics and Biosimilars, Pricing and Payment - Industry
None
Price and cost transparency: Requires manufacturer of prescription drug with annual wholesale acquisition cost of $10,000 or more, or with wholesale acquisition cost of $10,000 or more per course of treatment, to file annual report with Oregon Health Authority on costs associated with prescription drug for previous calendar year.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
61
OregonOR H 23872017
Pharmaceutical Manufacturer Reimbursement
Failed - Adjourned - Joint Committee on Ways and Means
Failed4/27/2017Health Care CmtJoint commiteeJoint commiteeBipartisanPricing and Payment - IndustryNone
Creates Oregon Premium Protection Program in Department of Consumer and Business Services and establishes Oregon Premium Protection Fund, requires pharmaceutical manufacturer to pay to department cost of prescription drug that exceeds specified threshold, requires department to use payments to reimburse insurers, third party administrators, Public EmployeesΓÇÖ Benefit Board, Oregon Educators Benefit Board, health care service contractors and other entities for incurred costs of drug that exceeds threshold.
R&D transparency
Manufacturers of drugs with an introductory wholesale prices of 12,000 or more per year shall report R&D costs, clinical trials costs
Drugs with high pricesR&D costs, clinical trial costs
62
PennsylvaniaPA H 10422016The Insurance Company Law of 1921
Pending - Carryover - House Insurance Committee
Pending4/21/2015
DeLuca (D) Additional Authors: Cohen (D);Acosta (D);McNeill (D);Grove (R);Costa D (D);Moul (R);Mahoney (D);Harkins (D);Cox (R);Pickett (R);Thomas (D);Hennessey (R);Parker D (R)
14BipartisanBipartisanPricing and Payment - Industry, AccessNone
Cost and price transparency: Amends the state insurance act, provides for pharmaceutical cost transparency. Establishes that for any ''prescription drug with an average wholesale price of $5,000 or more annually or per course of treatment, a health insurance policy or government program providing benefits for prescriptions shall not be required to provide the benefits if the manufacturer of the prescription drug has not filed a report on the drug'' that details the costs of production, research and development, clinical trials and regulatory requirements, marketing and other expenses.
R&D transparency
Manufacturers of drugs with wholesale prices of 5,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
No reinbursement
63
PennsylvaniaPA H 10422015The Insurance Company Law of 1921
Pending - House Insurance Committee
Pending4/21/2015
DeLuca (D) Additional Authors: Cohen (D);Acosta (D);McNeill (D);Grove (R);Costa D (D);Moul (R);Mahoney (D);Harkins (D);Cox (R);Pickett (R);Thomas (D);Hennessey (R);Parker D (R)
14BipartisanBipartisanPricing and Payment - Industry, AccessNone
Cost and price transparency: Amends the state insurance act, provides for pharmaceutical cost transparency. Establishes that for any ''prescription drug with an average wholesale price of $5,000 or more annually or per course of treatment, a health insurance policy or government program providing benefits for prescriptions shall not be required to provide the benefits if the manufacturer of the prescription drug has not filed a report on the drug'' that details the costs of production, research and development, clinical trials and regulatory requirements, marketing and other expenses.
R&D transparency
Manufacturers of drugs with wholesale prices of 5,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
64
Rhode IslandRI H 78392016Critical Prescription Drug List
Pending - House Corporations Committee
Pending3/3/2016
Fellela (D) Additional Authors: Ucci (D);Serpa (D);Azzinaro (D);Messier (D)
5DemocraticDemocraticPricing and Payment - Industry, AccessNone
Cost transparency for high-cost pharmaceuticals: Would require the Executive Office of Health and Human Services (""EOHHS"") to create a critical prescription drug list where there is a substantial public interest in understanding the development of its pricing. If a prescription drug is placed on the critical prescription drug list, the manufacture of such prescription drug must report certain information to EOHHS. This act would take effect on January 1, 2017.
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
65
Rhode IslandRI S 25602016Office of Health and Human Services
Pending - Senate HealthAnd Human Services Committee
Pending2/25/2016
Coyne (D) Additional Authors: DiPalma (D);Archambault (D);Goldin (D);Satchell (D)
5DemocraticDemocratic
Pricing and Payment - Industry, Access, Cost Sharing and Deductibles - Consumers
None
Cost and price transparency: Would require the Executive Office of Health and Human Services (""EOHHS"") to create a critical prescription drug list where there is a substantial public interest in understanding the development of its pricing. If a prescription drug is placed on the critical prescription drug list, the manufacture of such prescription drug must report certain information to EOHHS. This act would take effect on January 1, 2017. [Added 3/1/2016]
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
66
Rhode IslandRI S 4962018Office of Health and Human Services
Pending - Senate Health and Human Services Committee
Pending3/2/2017
Coyne (D) Additional Authors: Conley (D);Goldin (D);Satchell (D);Calkin (D)
5DemocraticDemocraticPricing and Payment - IndustryNone
Requires the Executive Office of Health and Human Services, EOHHS to create a critical prescription drug list where there is a substantial public interest in understanding the development of its pricing, requires if a prescription drug is placed on the critical prescription drug list, the manufacture of such prescription drug must report certain information to EOHHS, enables EOHHS to set maximum price limits on those drugs.
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
67
Rhode IslandRI S 4962017Office of Health and Human Services
Pending - Senate Health and Human Services Committee
Pending3/2/2017
Coyne (D) Additional Authors: Conley (D);Goldin (D);Satchell (D);Calkin (D)
5DemocraticDemocraticPricing and Payment - IndustryNone
Requires the Executive Office of Health and Human Services, EOHHS to create a critical prescription drug list where there is a substantial public interest in understanding the development of its pricing, requires if a prescription drug is placed on the critical prescription drug list, the manufacture of such prescription drug must report certain information to EOHHS, enables EOHHS to set maximum price limits on those drugs.
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug" list based on price and access criterias shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
68
TennesseeTN H 22062016
Price and Cost Information of Prescription Drugs
Failed - Adjourned - House Health Committee
Failed1/21/2016Mitchell (D)1DemocraticDemocraticPricing and Payment - Industry
TN S 2442 - Same as
Relates to prescription drug cost transparency, authorizes the department of health to require certain prescription drug manufacturers to disclose price and cost information, authorizes the department of health to set maximum prices for certain prescription drugs. If the department of health determines that a prescription drug price is significantly high, then the department of health may set the maximum allowable price that the manufacturer can charge for that prescription drug'' in the state.
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug list" based on price and access criterias shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
69
TennesseeTN S 24422016Prescription Drug Information
Failed - Adjourned - Senate CommerceAnd Labor Committee
Failed1/21/2016Harris (D)1DemocraticDemocraticPricing and Payment - Industry
TN H 2206 - Same as
Authorizes the Department of Health to ''develop a list of critical prescription drugs for which there is a substantial public interest in understanding the development of the drugs' pricing.'' require certain prescription drug manufacturers to disclose price in-state compared to prices in other countries, and cost of research, production, marketing information. If the department of health determines that a prescription drug price is significantly high, then it ''may set the maximum allowable price that the manufacturer can charge for that prescription drug that is sold for use in the state.''
R&D transparency
Manufacturers of drugs placed on a "critical prescription drug list" based on price and access criterias shall report R&D costs, subsidies
Drugs with high pricesR&D costs, subsidies
70
TexasTX H 40022015
International Pharmaceuticals Price Discrimination
Failed - Adjourned - House InternationalTradeAnd IntergovernmentalAffairs Committee
Failed3/13/2015Burrows (R)1RepublicanRepublicanPricing and Payment - Industry, AccessNone
Price and cost transparency: provides for an interim study regarding international price discrimination in pharmaceuticals.
R&D transparency
A joint interim committee on drug pricing shall consider R&D subsidies
Drugs with high pricesR&D costs
71
VermontVT H 8662016
Prescription Drug Manufacturer Cost Transparency
Failed - Adjourned - House Health Care Committee
Failed3/11/2016Health Care CmtJoint commiteeJoint commiteeBipartisanPricing and Payment - IndustryNone
Relates to requiring prescription drug manufacturer cost transparency.
R&D transparency
Manufacturers of drugs placed on a list based based on State healthcare spending shall report R&D cost, clinical trials, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
72
VirginiaVA H 14362018Prescription Drug Price TransparencyFailed - DiedFailed1/16/2018
Hurst (D) Additional Authors: Plum (D);Edwards (D);Hope (D);Simon (D);Boysko (D);Krizek (D);Levine (D);Gooditis (D)
9DemocraticDemocratic
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs
None
Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the state and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the State Health Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per treatment or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
73
VirginiaVA H 11132017Prescription Drug Price TransparencyFailed - Adjourned - HOUSEFailed1/13/2016Hugo (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
74
VirginiaVA H 11132016Prescription Drug Price TransparencyPending - Carryover - HOUSEPending1/13/2016Hugo (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
75
VirginiaVA S 4872016Prescription Drug Price Transparency
Pending - Carryover - SenateEducationAnd Health Committee
Pending1/13/2016Hanger (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Relates to prescription drug price transparency, requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
76
WashingtonWA S 55862018Prescription Drug Cost Transparency
Failed - Adjourned - IndefinitelyPostponed
Failed1/30/2017Ranker (D)1DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
77
WashingtonWA S 54012018Prescription Drug Cost Transparency
Failed - Adjourned - Senate Health & LongTerm Care Committee
Failed1/23/2017Rivers (R)1RepublicanRepublican
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs
WA H 1541 - Companion
Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices and price increases
R&D costs, clinical trial costs, subsidies
78
WashingtonWA S 55862017Prescription Drug Cost Transparency
Pending - Carryover - Senate Health Care Committee
Pending1/30/2017Ranker (D)1DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Addresses prescription drug cost transparency, requires the state to collect, verify, and summarize prescription drug pricing data provided by health insurance issuers and manufacturers. A manufacturer with a drug that increases more than 10% or $10,000 in a year must report for such drug, the time on the market, the generic or brand name status, pricing history in the US the previous five years, total financial assistance given by the manufacturer through assistance programs, rebates, and coupons, and an economic justification of the qualifying price increase for the covered drug. Any qualifying price increase for a covered drug must be announced 60 days before the change. Separately, each health insurance plan issuer must identify overall spending on prescription drugs and by the 25 most frequently prescribed drugs, the 25 costliest prescription drugs, with the information by the state Medicaid program, public employees' benefits board programs, and the individual, small group, and large group markets. All data submitted must be collected by a state-approved data organization and made publicly available on the office's web site, with reports due starting Nov. 1, 2017. Fines may be up to $1000 per day for non-compliance.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment or with price increases shall report R&D costs, clinical trials costs
Drugs with high prices and price increasesR&D costs, clinical trial costs
79
WashingtonWA H 23632016
Pharmaceutical Drug Cost and Utilization Transparency
Failed - Adjourned - House Health CareAnd Wellness Committee
Failed1/11/2016Cody (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Concerns pharmaceutical drug cost and utilization transparency.
R&D transparency
Manufacturers of drugs with wholesale prices of 10,000 or more per year or treatment shall report R&D costs, clinical trials costs, subsidies
Drugs with high prices
R&D costs, clinical trial costs, subsidies
80
MaineME S 4322018Generic Drug PricingPending - SENATEPending6/23/2017
Jackson (D) Additional Authors: Davis P (R);Saviello (R);Gattine (D);Mastraccio (D);Vitelli (D);Lawrence (D);Bellows (D);Carson (D)
9BipartisanBipartisanClinical Trials and Right to TryNone
Summary This bill amends the Maine Pharmacy Act to require that a drug distributed in this State must be made available for sale in this State to a person seeking to develop an application for the approval of the drug under the Federal Food, Drug, and Cosmetic Act or the licensing of a biological product under the federal Public Health Service Act. It establishes disciplinary actions for noncompliance.
REMS abuses
Manufacturers of certain drugs shall make them available to an eligible product developer for purposes of conducting testing
-
81
ArizonaAZ H 21072018
Prescription Drug Pricing Patient Notification Act
Enacted - Act No. 133Enacted04/05/2018 - Enacted
Syms (R) Additional Authors: Barton (R);Boyer (R);Finchem (R);Kern (R);Weninger (R)
6RepublicanRepublican
Pricing and Payment - Industry, Pharmacy Benefit Managers (PBM)
None
Relates to prescription drug costs: Provides that a PBM (pharmacy benefits manager) or other entity that administers prescription drug benefits 'may not prohibit by contract a pharmacy or pharmacist from informing the patient that the patient may be able to procure a prescription medication at a lower cost, including by paying the cash price.'' (no 'gag' clauses) [Updated 4/16/2018]
Transparency, but not on R&D
PBMs cannot prohibit a pharmacy to disclose information on price of a drug or affordable alternatives to an insured
82
ArkansasAR HR 10132015Cost of Generic Prescription MedicationsAdopted - AdoptedAdopted02/18/2015 - EnactedBoyd (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Encourages the United States Congress to investigate the increases in cost of generic prescription medications, urges the Food and Drug Administration to review federal regulations concerning generic pharmaceutical manufacturers.
Transparency, but not on R&D
83
ArkansasAR HR 10122015
Increases in Cost of Generic Prescription Medications
Failed - Adjourned - WithdrawnFailed2/5/2015Boyd (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Encourages the United States congress to investigate the increases in cost of generic prescription medications, urges the food and drug administration to review federal regulations concerning generic pharmaceutical manufacturers.
Transparency, but not on R&D
84
CaliforniaCA S 172017Health Care: Prescription Drug CostsEnacted - Act No. 2017-603Enacted10/09/2017 - Enacted
Hernandez (D) Additional Authors: Chiu (D);Wood (D)
3DemocraticDemocraticPricing and Payment - IndustryNone
Requires pharmaceutical manufacturers to submit to public and private purchasers (including state agencies, health insurers, and pharmacy benefit managers) 90-day advance notification of price increases for prescription drugs currently on the market, including detailed information regarding the reasons and justification for such increases, as well as justification of launch prices for new drugs. Requires health insurers that file rate information to report specified cost information regarding covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs. Requires reporting the percentage of the insurance premium attributable to prescription drugs.
Transparency, but not on R&D
85
CaliforniaCA SJR 292016EpiPen: PricingAdopted - Act No. 191Adopted09/09/2016 - Enacted
Hernandez (D) Additional Authors: Leno (D);Hall (D)
3DemocraticDemocraticPricing and Payment - Industry, AccessNone
Relates to EpiPen pricing. Urges the U.S. Food and Drug Administration (FDA)to reconsider its denial of approval for generic alternatives to the epinephrine auto-injector EpiPen. Urges the Congress of the United States to investigate the impact that Mylan NV's monopoly has had on price increases for EpiPen. Urges the Congress and the President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based on what the market can bear.
Transparency, but not on R&D
86
CaliforniaCA S 10102016Health Care: Prescription Drug Costs
Failed - Adjourned - Assembly InactiveFile
Failed8/16/2016
Hernandez (D) Additional Authors: Chiu (D)
2DemocraticDemocratic
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Rx Transparency: Requires a drug manufacturer to inform State purchasers, health care service plans, health insurers and chairs of specified legislative committees about increases of 10% or more in the wholesale acquisition cost of drugs and of the introduction to market of a prescription drug that has a wholesale acquisition cost of $10,000 or more annually or per course of treatment, and report specified information regarding the drug price. Requires health insurers that file rate information to report the 25 most frequently prescribed drugs and the average wholesale price for each drug and the 25 most costly drugs by total plan or insurer spending and the average wholesale price for each drug. Relates to submission of rate increases for all large group benefit plans. Failure to comply in 30 days may result in a civil penalty of $1,000 per day.
Transparency, but not on R&D
87
ColoradoCO H 11792018Prohibit Price Gouging on Prescription DrugsFailed - Adjourned - HOUSEFailed2/2/2018Salazar (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Concerns a prohibition against price gouging on certain prescription drugs.
Transparency, but not on R&D
Attorney General may require info on cost of producing a drug, circunstances and timming of the price increase
88
ColoradoCO H 12602018Prescription Drug Price Transparency
Failed - Adjourned -Postponed Indefinitely
Failed4/12/2018
Ginal (D) Additional Authors: Moreno (D);Jackson (D)
3DemocraticDemocratic
Pricing and Payment - Industry, Pharmacy Benefit Managers (PBM)
None
Concerns prescription drug price transparency, enacts the ""Colorado Prescription Drug Price Transparency Act of 2018"", which requires health insurers to submit to the commissioner of insurance information regarding drug prescription coverage, prescription drug manufacturers to notify health insurer, state purchased and pharmacy benefit management firms price increases and specify new speciality drugs on the market.
Transparency, but not on R&D
Report on the 25 costliest drugs and 25 drugs with the highest year-over-year cost increases
89
ColoradoCO S 1522018Prohibit Price Gouging on Prescription Drugs
Failed - Adjourned -Postponed Indefinitely
Failed1/29/2018
Aguilar (D) Additional Authors: Lontine (D)
2DemocraticDemocraticPricing and Payment - IndustryNone
Concerns a prohibition against price gouging on certain prescription drugs.
Transparency, but not on R&D
90
ConnecticutCT S 9252017Prescription Drugs Costs
Failed - Adjourned - Legislative Commissioner's Office
Failed3/30/2017
Joint Insurance and Real Estate Additional Authors: Looney (D)
Joint commiteeJoint commiteeBipartisanPricing and Payment - IndustryNone
Concerns the cost of prescription drugs and value-based insurance design, requires manufacturers of prescription drugs to disclose pricing information to the Insurance Commissioner, requires that certain insurance policies incorporate value-based insurance design, establishes a task force to study methods of controlling the cost of prescription drugs.
Transparency, but not on R&D
91
FloridaFL S 14942018Prescription Drug Price TransparencyFailed -TabledFailed2/20/2018
Montford (D) Additional Authors: Grimsley (R);Broxson (R);Powell (D);Gainer (R)
5BipartisanBipartisanPricing and Payment - Industry
FL H 351 - Similar
Relates to prescription drug pricing transparency, requires a pharmacist to inform a customer of a lower cost alternative to a prescription and of whether the customers cost-sharing obligation exceeds the retail price of the prescription, defines the term pharmacy benefit manager, requires a pharmacy benefit manager to register with the Office of Insurance Regulation.
Transparency, but not on R&D
92
FloridaFL H 5892017Prescription Drug Price TransparencyEnacted - Act No. 2017-86Enacted06/09/2017 - Enacted
Yarborough (R) Additional Authors: Magar (R);Renner (R);Baez (D);White (R)
5BipartisanBipartisanPricing and Payment - IndustryNone
Relates to prescription drug price transparency, requires the Agency for Health Care Administration to collect data on retail prices charged by pharmacies for the most frequently prescribed medicines, requires the agency to update its website monthly.
Transparency, but not on R&D
93
FloridaFL S 8882017Prescription Drug Price TransparencyFailed -TabledFailed3/7/2017Bean (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Relates to prescription drug price transparency, requires the Agency for Health Care Administration to collect data on the retail prices charged by pharmacies for the 300 most frequently prescribed medicine.
Transparency, but not on R&D
94
IllinoisIL H 49002018Generic Drug Pricing Fairness Act
Pending - Senate Judiciary Committee
Pending2/14/2018
Guzzardi (D) Additional Authors: Demmer (R);Stadelman (D);Harris N (D);Cullerton T (D);Bush (D);Bertino-Tarrant (D);Willis (D);Welch (D);Tabares (D);Moylan (D);Mitchell C (D);Kifowit (D);Van Pelt (D);Moeller (D);Carroll (D);Castro (D);Aquino (D);Stuart (D);Stratton (D);Mah (D);Murphy L (D);Harper (D);Bennett (D);Ammons (D);Wallace (D);Smith (D);Fine (D);Evans M (D);Raoul (D);Hunter (D);Sandoval (D);Martinez (D);Collins J (D);Chapa-LaVia (D);Lightford (D);Silverstein (D);Lang (D);Flowers (D);Hernandez (D);Holmes (D);Koehler (D);Cassidy (D);McCann (R);Biss (D);Gabel (D);Lilly (D);Jones (D);Hutchinson (D);Zalewski (D);Steans (D);Riley (D);Currie (D)
53BipartisanBipartisanPricing and Payment - IndustryNone
Creates the Generic Drug Pricing Fairness Act, provides that a manufacturer or wholesale drug distributor shall not engage in price gouging in the sale of an essential off-patent or generic drug, provides that the Director of Healthcare and Family Services or Director of Central Management Services may notify the Attorney General of any increase in the price of any essential off-patent or generic drug under the Medical Assistance Program under the Public Aid Code or a State health plan.
Transparency, but not on R&D
95
IllinoisIL H 2392017Food Drug and CosmeticPending - House Rules CommitteePending1/11/2017
Flowers (D) Additional Authors: Lilly (D);Jones T (D);Manley (D);Tabares (D);Welch (D)
6DemocraticDemocratic
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs
None
Amends the Food, Drug and Cosmetic Act, requires manufacturers of brand name or generic prescription drugs to notify State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly of specified increases in drug prices at least 60 days before such increase and the cost of specified new prescription drugs within 3 days after approval by the U.S. Food and Drug Administration.
Transparency, but not on R&D
96
IndianaIN H 13452018Prescription Drug Pricing Study
Failed - Adjourned - HousePublic Health Committee
Failed1/12/2018Shackleford (D)1DemocraticDemocraticPricing and Payment - IndustryNone
Relates to conducting a state prescription drug pricing study, urges the legislative council to assign to the interim study committee on public health, behavioral health, and human services the task of studying issues related to prescription drug price transparency by drug manufacturers in Indiana.
Transparency, but not on R&D
Report on the effect that significant price increases have on access
97
KansasKS H 23002017Rx Transparency Act
Pending - Carryover - House HealthAnd Human Services Committee
Pending2/7/2017
Health and Human Services Cmt
Joint commiteeJoint commiteeBipartisan
Pricing and Payment - Industry, Insurance/Coverage - Rx Drugs, Pharmacy Benefit Managers (PBM)
None
The Rx transparency act requires that PBMs contracting with the state (employee) health care benefits program act as a fiduciary and disclose any payment or benefit received for the dispensing of a prescription drug. The PBM would also disclose all financial and utilization information requested by the program. Any payment or benefit received by the PBM for the dispensing of a prescription drug will be passed-through in full to the state.
Transparency, but not on R&D
98
LouisianaLA S 2832018Health InsuranceEnacted - Act No. 371Enacted05/20/2018 - EnactedMills (R)1RepublicanRepublican
Pricing and Payment - Industry, Pharmacy Benefit Managers (PBM)
None
Relates to pharmacy benefit managers, provides for internet publication of formularies, provides for transparency reporting, provides for certain reportable aggregate data, provides for internet publication of the transparency report, provides for definitions, provides for the duties of the commissioner of insurance relative thereto, provides for confidentiality.
Transparency, but not on R&D
PBMs shall submit an annual transparency report
99
LouisianaLA H 2432018Drugs and PrescriptionFailed - Adjourned - HOUSEFailed4/12/2018Talbot (R)1RepublicanRepublican
Pricing and Payment - Industry, Cost Sharing and Deductibles - Consumers
None
Prohibits a manufacturer or wholesale distributor from engaging in price gouging in the sale of an essential off-patent or generic drug.
Transparency, but not on R&D
Attorney General may require info on cost of producing a drug, circunstances and timming of the price increase
100
LouisianaLA H 7102018Drugs and Prescription
Failed - Adjourned - House HealthAnd Welfare Committee
Failed3/20/2018Hollis (R)1RepublicanRepublicanPricing and Payment - IndustryNone
Prohibits a manufacturer or wholesale distributor from engaging in unrestrained price increases in the sale of an essential off-patent or generic drug.
Transparency, but not on R&D
Attorney General may require info on cost of producing a drug, circunstances and timming of the price increase
Loading...